ArticleFrontiers in pharmacology2023

Post-marketing safety surveillance of dalfampridine for multiple sclerosis using FDA adverse event reporting system.

Rui Xiong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.